between metabolic and cardiovascular pathways. Unfortunately, STOP-NIDDM was not designed to characterise the mechanisms of acarbose action.
We here investigated whether acarbose-induced modulation of postprandial glucose levels affects mid-regional proatrial NP (MR-proANP), which is a stable fragment of Nterminal pro-atrial NP (proANP). This was a single-centre double-blind randomised placebo-controlled crossover study in individuals with different stages of glucose tolerance ( Fig. 1 ; registered trial number ISRCTN40281673; the complete information regarding participants' allocation, primary outcome and side effects has previously been published in Rudovich et al [7] ). Following a wash-out period of glucoselowering medication for at least 3 weeks, the participants were randomised to one of two interventions: placebo-acarbose (n 032) and acarbose-placebo (n 031). Four individuals discontinued the study because of dissatisfaction with the allocated intervention or lack of time to participate. Three individuals were excluded because of adverse events (gastrointestinal discomfort, all receiving acarbose treatment), and one was excluded because of a drug-unrelated serious adverse event (ischaemic insult). Thus, 55 participants (n020 individuals with type 2 diabetes; n035 individuals without diabetes) were eligible for the final analyses. 6 .2±0.8/5.7±0.5%) of study participants were published recently [7] . Eligible patients were randomised to receive either acarbose (300 mg/day in three divided doses; Glucobay, BayerVital, Leverkusen, Germany) followed by placebo or vice versa, with each administered for 12 weeks, with a 12 week wash-out between interventions. Liquid-meal challenge tests were performed for 240 min using a commercial preparation (Biosorb Energie; Pfrimmer Nutricia, Erlangen, Germany; 77.6 g carbohydrate, 22.3 g fat, 24 g protein, 2,510 kJ per 400 ml) after a 12 h overnight fast. In accordance with the treatment period, either 100 mg acarbose or placebo was given immediately at the start of the meal challenges. Pretreatment experiments were conducted without drug exposition. Further venous blood samples for the analysis of hormones and blood glucose were taken at −20, −10, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210 and 240 min, timed from ingestion of the meal. Changes in fasting MR-proANP were measured using an immunoassay (MR-proANP immunoluminometric assay (LIA); BRAHMS, Hennigsdorf, Germany).
Individuals with type 2 diabetes had higher HbA 1c levels and postprandial glycaemic responses, but the anthropometric data and lipid profiles were not different between the groups (data not shown). During the 12 weeks of treatment, no significant changes in body weight were observed with exposure to placebo or acarbose (Table 1) . Nevertheless, all analyses of acarbose effects were adjusted for changes in body weight. Fasting blood glucose and insulin levels remained unchanged during acarbose treatment in both groups (data not shown). As expected, a moderate but significant reduction of postprandial glycaemia by acarbose was observed during the liquid-meal tests ( Table 1 ). The effect on postprandial blood glucose levels was accompanied by a decrease in postprandial insulin concentrations during acarbose treatment (Table 1 ). In individuals without diabetes, fasting levels of MR-proANP increased after 12 weeks of acarbose treatment (median [range] 23.6% of baseline [from +37.1 to +12.7%], p00.001; Table 1 ). Moreover, changes in fasting MR-proANP levels (week0-week 12) correlated negatively with changes in the incremental AUC Δ AUCinsulin (week0-week12) (r0−0.53, p<0.0001) and with changes in Δ AUCglucose (week 0-week12) was observed (r0−0.32, p00.02). In individuals with type 2 diabetes, changes in fasting MR-proANP levels failed to reach significance. This was probably related to reduced power in Acarbose-placebo sequences 6 subjects discontinued: 1 SAE (drug unrelated) 3 AE (gastrointestinal discomfort) 2 individuals (personal reasons) Placebo-acarbose sequences 2 individuals discontinued: 2 individuals (personal reasons) Fig. 1 Study design and participants' disposition. This was a singlecentre double-blind randomised placebo-controlled crossover study in individuals with different stages of glucose tolerance. Placebo and acarbose were administered in the same manner. (S)AE, (serious) adverse effect; TID, three times daily this smaller subgroup, though a potential influence of treatment e.g. with metformin on MR-proANP levels cannot be finally excluded (Table 1) .
Treatment with acarbose led to an increase in MRproANP levels in individuals without diabetes that was strongly correlated with a reduction of postprandial insulin and glucose levels. Thus, although the observed acarboseinduced increase in circulating MR-proANP levels was relatively small, it still may contribute to assumed cardioprotective and antihypertensive effects of this drug, as indicated by results from the STOP-NIDDM study, and may provide further evidence for the existence of a 'common cardiometabolic pathway' [1, 2] .
We observed no significant changes in body weight, insulin sensitivity or markers of systemic inflammation in the present study during the 3 month acarbose treatment [7] , supporting that treatment with acarbose might have influenced the observed upregulation of MR-proANP via changes in postprandial insulin responses, and further indicating a potential direct role of insulin in the regulation of ANP-secretion and/or clearance [3] .
Given the careful selection of our study participants, all participants had comparable insulin sensitivity and seemed to be in good glycaemic control [7] ; we were, however, unable to demonstrate a significant increase in MR-proANP in the individuals with type 2 diabetes, possibly because of the short treatment time, issues related to reduced power in this subgroup, and potential effects of pre-treatment with other drugs such as metformin. Another explanation may be loss of insulin-dependent regulation of ANP in individuals with diabetes. Further studies are needed to investigate the potential relation between glucose and insulin-modulating effects of glucose-lowering drugs and their consequences regarding the NP system and potential prevention of CVD.
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